BCL11B and acute lymphoblastic leukemia: BCL11B altered ETP-ALL is associated with FLT3 alterations [14, 17, 87] indicating first or second generation FLT3 kinase inhibitors such as sorafenib or quizartinib as potential therapeutics in this subtype when a FLT3 alteration is present [25, 88].